BMO Capital analyst Etzer Darout initiates coverage on $Protagonist Therapeutics (PTGX.US)$ with a buy rating, and sets the target price at $62.
According to TipRanks data, the analyst has a success rate of 59.6% and a total average return of 37.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Protagonist Therapeutics (PTGX.US)$'s main analysts recently are as follows:
Protagonist Therapeutics' Phase 3 assets are considered to have commercial potential, although they have been licensed which offers 'limited' financial and M&A upside. The substantial over 400% increase in the company's stock price over the past two years can be attributed to development progression and licensing deals, suggesting that the current price already accounts for the anticipated benefits from these assets.
Protagonist Therapeutics is capitalizing on its peptide technology platform to tackle disorders in hematology and immunology. The company's stock is projected to gain in value following significant clinical advancements over the coming year, bolstered by key developments with rusfertide and JNJ-2113. Additionally, Protagonist is poised to offer oral medication alternatives in highly lucrative markets predominantly occupied by injectable therapies.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BMO資本市場分析師Etzer Darout首次給予$Protagonist Therapeutics (PTGX.US)$買入評級，目標價62美元。
根據TipRanks數據顯示，該分析師近一年總勝率為59.6%，總平均回報率為37.0%。
此外，綜合報道，$Protagonist Therapeutics (PTGX.US)$近期主要分析師觀點如下：
Protagonist Therapeutics的第三階段資產被認爲具有商業潛力，儘管它們已獲得許可，但其財務和併購上行空間 「有限」。在過去兩年中，該公司股價大幅上漲了400％以上，這可以歸因於開發進展和許可協議，這表明當前的價格已經考慮了這些資產的預期收益。
Protagonist Therapeutics正在利用其肽技術平台來解決血液學和免疫學方面的疾病。在rusfertide和 JNJ-2113 的關鍵進展的推動下，在來年取得重大臨床進展之後，該公司的股票價值預計將上漲。此外，Protagonist準備在主要由注射療法佔據的利潤豐厚的市場中提供口服藥物替代品。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
